Please check your internet connection and try again.
# Hyoscine butylbromide
## Overview
Hyoscine butylbromide (Scopolamine butylbromide) is a quaternary ammonium antispasmodic agent. Unlike hyoscine hydrobromide, it does not cross the blood-brain barrier effectively, resulting in fewer central nervous system side effects. It exerts a selective antispasmodic effect on the smooth muscle of the gastrointestinal, biliary, and urinary tracts.
## Primary Indications
* Symptomatic relief of gastrointestinal and genitourinary tract spasms.
* Spasticity of the gastrointestinal tract (e.g., irritable bowel syndrome).
* Diagnostic radiology (as an antispasmodic).
## Adult Dosing
* **Oral:** 10 mg to 20 mg three to four times daily. Maximum daily dose: 100 mg.
* **IV/IM/SC:** 20 mg as a single dose. May repeat after 30 minutes if necessary. Maximum daily dose: 100 mg.
## Pediatric Dosing
* **Children 6 to 12 years:** 10 mg (one tablet) three times daily (oral).
* **Parenteral:** Not routinely recommended for children; if required, dose should be directed by pediatric specialist protocols (common range: 0.3–0.6 mg/kg/dose).
## Dose Adjustments
* **Renal/Hepatic Impairment:** No formal standardized adjustment, but use with caution; clinical supervision is advised due to potential for reduced clearance.
* **Elderly:** Use lower starting doses and monitor for urinary retention or tachycardia.
## Contraindications
* Hypersensitivity to hyoscine butylbromide.
* Myasthenia gravis.
* Megacolon.
* Paralytic ileus or intestinal obstruction.
* Narrow-angle glaucoma.
* Tachycardia or unstable cardiovascular status.
* Prostatic hypertrophy with urinary retention.
## Adverse Effects
* **Common:** Tachycardia, dry mouth, blurred vision (accommodation disturbances), and urinary retention.
* **Serious:** Anaphylaxis, cardiac arrhythmias, and acute angle-closure glaucoma.
## Key Drug Interactions
* **Anticholinergics (e.g., TCAs, antihistamines):** Additive anticholinergic effects (dry mouth, urinary retention, confusion).
* **Dopamine antagonists (e.g., Metoclopramide):** Antagonistic effects on GI motility—avoid concomitant use.
* **Tachycardia-inducing agents:** May potentiate the tachycardic effect of beta-agonists.
## Monitoring
* Heart rate and rhythm (especially with parenteral administration).
* Bladder function (assess for urinary retention).
* Ocular assessment (visual disturbances).
* Monitor GI motility to ensure no progression into paralytic ileus.
## Clinical Pearls
* **BBB Penetration:** Because it is a quaternary ammonium compound, it has poor lipid solubility and does not cross the blood-brain barrier; therefore, it does not produce the sedation or memory impairment associated with hyoscine hydrobromide.
* **Parenteral Use:** IV administration must be performed slowly. Advise patients of potential tachycardia and temporary visual blurring after injection.
* **Local Protocols:** Significant variability exists in parenteral dosing for acute colic; always verify institutional guidelines before administration.
***
*Disclaimer: This information is for educational purposes only. Clinical practice varies by region and institution. Please consult the current official Summary of Product Characteristics (SmPC) or your local formulary/prescribing guidelines before prescribing or administering any medication.*
